Zilovertamab Adds Pharmacology, Not Broad CLL Efficacy
A peer-reviewed Phase 1b/2 study of zilovertamab plus ibrutinib shows ROR1 occupancy and pathway modulation, but the small randomized cohort did not improve complete response, overall response or progression-free survival versus ibrutinib alone. An…
